Case Report

An overlap of Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy/dysplasia

Shohei Kataoka, MD*, Naoki Serizawa, MD, Kazutaka Kitamura, MD, Atsushi Suzuki, MD, Tsuyoshi Suzuki, MD, Tsuyoshi Shiga, MD, Morio Shoda, MD, Nobuhisa Hagiwara, MD

Department of Cardiology, Tokyo Women’s Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo 162-8666, Japan

A R T I C L E   I N F O
Article history:
Received 15 July 2015
Received in revised form 25 October 2015
Accepted 29 October 2015
Available online 30 November 2015

Keywords:
Brugada syndrome
Arrhythmogenic right ventricular cardiomyopathy/dysplasia
An overlap disease

A B S T R A C T
Overlapping characteristics of Brugada syndrome (BrS) and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) have been reported in recent studies, but little is known about the overlapping disease state of BrS and ARVC/D. A 36-year-old man, hospitalized at our institution for syncope, presented with this overlapping disease state. The electrocardiogram showed spontaneous coved-type ST-segment elevation, and ventricular fibrillation was induced by right ventricular outflow tract stimulation in an electrophysiological study. BrS was subsequently diagnosed; additionally, the presence of epsilon-like waves and right ventricular structural abnormalities met with the 2010 revised task force criteria for ARVC/D. After careful investigation for both BrS and ARVC/D, an implantable cardioverter defibrillator was inserted in the patient. This case revealed 2 important clinical findings: (1) BrS and ARVC/D clinical features can coexist in a single patient, and EPS might be useful for determining the phenotype of overlapping disease (e.g., BrS-like or ARVC/D-like). (2) An overlapping disease state of BrS and ARVC/D can change phenotypically during its clinical course. Therefore, careful examination and attentive follow-up are required for patients with BrS or ARVC/D.

© 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Brugada syndrome (BrS) is characterized by right precordial ST-segment elevation followed by a negative T wave and sudden cardiac death from ventricular fibrillation in patients with structurally normal hearts [1]. Recent studies have revealed structural or electrocardiographic abnormalities, such as right ventricular dilatation or epsilon-like waves, in some patients with BrS [2,3]. These abnormalities are commonly considered characteristics of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). It is generally known that there are clinical similarities between BrS and ARVC/D [4]; however, little is known about the clinical features of patients with an overlapping disease state of BrS and ARVC/D, and accordingly, treatment of such patients remains poorly understood. In order to understand this condition better, we report here, a case of overlapping disease state of BrS and ARVC/D.

2. Case report

A 36-year-old man presented to our institution with syncope, and was subsequently, hospitalized. He had no family history of sudden cardiac death. The electrocardiogram (ECG) showed spontaneous coved-type ST-segment elevation (Brugada type 1 ECG); we initially suspected BrS. In an electrophysiological study (EPS) conducted prior to pilsicainide infusion, neither ventricular tachycardia (VT) nor ventricular fibrillation (VF) was induced by a single or double stimulus to the right ventricular apex or right ventricular outflow tract. A single stimulus to the right ventricular outflow tract during pilsicainide infusion induced ventricular fibrillation, which was thereafter, inhibited during isoproterenol infusion. Therefore, the patient was diagnosed with BrS, although the clinical presentation differed from typical BrS to some extent. First, the chest radiograph and cardiovascular magnetic resonance imaging (CMR) showed mild right ventricular (RV) dilatation (Fig.1A, B). Second, RV angiography demonstrated RV dilatation and akinesis in the inferior wall (Fig.1C, D), although coronary angiography did not show critical stenosis, and the provocation test failed to induce coronary spasm. Finally, epsilon-like waves were seen in spontaneous type 1 ECG (Fig.2). As a result, the patient not only met the diagnostic criteria for BrS but also met the
Fig. 1. (A) Chest radiograph reveals mild right ventricle dilatation. (B) Cardiovascular magnetic resonance imaging shows mild right ventricle dilatation and no late gadolinium enhancement. (C) Right ventricular angiography demonstrates right ventricular dilatation and akinesis in the inferior wall. (D) Computed tomography does not reveal fatty change in the right ventricular myocardium.

Fig. 2. The patient’s electrocardiogram shows spontaneous coved-type ST-segment elevation and epsilon-like waves in type 1 ECG.
Epsilon-like waves are more common in drug-induced type 1 ECGs than in spontaneous type 1 ECGs [3]. Rather than using the term “epsilon wave,” we use the term “epsilon-like wave” because distinguishing the epsilon wave from the fragmented QRS wave was difficult. The epsilon wave is located between the end of the QRS complex and beginning of the T-wave. In contrast, a fragmented QRS (f-QRS) is defined as the presence of additional spikes within the QRS complex. In patients with BrS, defining the end of QRS complex is difficult, and it is still controversial where the J wave represents depolarization component or repolarization component. Therefore, occurrence of additional spikes at the end of QRS complex or immediately after the QRS complex in BrS is not certain. The term “epsilon-like wave” has been used to avoid such discrepancies in ECG interpretation. [3] Some previous studies revealed that epsilon potentials and QRS fragmentation have similarly high diagnostic values, and epsilon-like potentials in different leads at the beginning, top, or end of the QRS complex are typical ECG findings in patients with ARVC/D. [6,7]. Second, imaging studies have revealed RV wall motion abnormalities or RV dilatation, which are characteristic of ARVC/D, in some patients with BrS [2,8]. Third, the fibro-fatty replacements required to diagnose ARVC/D have been detected during endocardial biopsies of patients with type 1 ECG [9]. Finally, specific gene mutations involving ARVC/D have been identified in some patients with BrS [10]. These overlapping features are considered a result either of genetic interactions or of the combined influence of BrS’ electrophysiological abnormalities and ARVC/D’s structural abnormalities. Accordingly, ARVC/D patients can satisfy the diagnostic criteria of BrS, and BrS patients can satisfy the diagnostic criteria of ARVC/D.

A disease state combining both conditions has a different clinical course than uncomplicated BrS. A subgroup of BrS patients may demonstrate the features of ARVC/D long after the initial BrS diagnosis. Structural heart diseases and histological findings consistent with ARVC/D have been revealed after autopsy of patients who were diagnosed with BrS and who died suddenly [11]. Thus, careful observation of the changing clinical course is vital and may indicate the transformation from BrS to ARVC/D.

Detailed evaluation in the cases of suspected overlap of BrS and ARVC/D is also needed to determine a better treatment course for these patients. In this case, we used a range of methods, from physical examination to genetic testing (BrS- and ARVC/D-specific), to confirm dual diagnosis and to determine a better course

### Table 1
Clinical characteristics of the present case.

| Characteristics of ARVC/D | Symptoms | Family history of ARVC/D | RV angiography | ECG depolarization | Late potentials | ECG changes | Imaging | Gene mutation of ARVC/D |
|---------------------------|----------|--------------------------|----------------|--------------------|----------------|------------|--------|----------------------------|
|                           | Syncope  | None                     | Regional RV akinesis | Epsilon wave | f-QRS=174 ms, LAS40=79 ms, RVEF=43% | Fixed       | RV dilatation | None                       |
|                           |          |                          |                 |                    |                         |            |        |                            |

### Table 2
Analyzed gene mutations.

| Gene          | Phenotype |
|---------------|-----------|
| RYR2         | CPVT1/ARVC2 |
| SCN5A        | LQTS/Brs1 |
| CACNA1C      | LQTS/Brs3 |
| CACNB2       | Brs4      |
| CACNA2D1     | Brs9      |
| SCN1B        | Brs5      |
| SCN3B        | Brs7      |
| GPD11        | Brs2      |
| KCNED3       | Brs10     |
| KCNJ8        | ER51/Brs8 |
| KCNE3        | Brs6      |
| KCNE4        |           |
| KCNES        | Brs1/IVF  |
| SCN10A       | Brs5      |
| MOG1 (RANGF) | Brs11     |
| DSP          | ARVC8     |
| PKP2         | ARVC9     |
| DSC2         | ARVC10    |
| DSC2         | ARVC11    |
| JUP          | ARVC12    |
of treatment (Tables 1, 2). Since this patient experienced an episode of syncope, demonstrated epsilon-like waves in spontaneous type 1 ECG, and showed RV dilatation and RV wall motion abnormalities, a diagnosis of overlap disease of BrS and ARVC/D for the patient can be asserted with certainty.

Although treating patients with BrS features in the case of structural heart disease remains challenging, this patient received an ICD because of spontaneous type 1 ECG and an episode of syncope. Nevertheless, the phenotype of this case may change in future, demonstrating clinical features of ARVC/D, such as symptoms of heart failure and RV arrhythmias.

Characteristic clinical features of an overlap disease of BrS and ARVC/D remain unclear, and consensus on a better treatment course for this type of overlap disease remains. After studying the present case, we recommend EPS evaluation to determine the phenotype of overlapping disease (e.g., BrS-like or ARVC/D-like) because clinical features of BrS and those of ARVC/D can coexist in a single patient. The phenotype observed in this case resembled BrS rather than ARVC/D. This case had neither late gadolinium enhancement on CMR nor inducibility of VT/VF during EPS before pilsicainide infusion. Therefore, the existence of scar areas or substrates, which are characteristics of ARVC/D, was unlikely. VF was easily inducible after pilsicainide infusion and was obviously inhibited after ISP infusion. These findings exactly match the characteristics of BrS. Identification of the phenotype of overlapping disease is important because responses to exercises or drugs, such as beta stimulants or sodium channel blockers, differ considerably between BrS and ARVC/D. In addition, upon confirmation of the overlap state, the clinician should recall that the phenotype may change during the clinical course. Therefore, more attentive follow-up is required. As more cases are discovered and reported, this disease state will be expected to be clarified further.

Conflict of interest

No authors in this study report a conflict of interest or need for financial disclosure.

References

[1] Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111:659–70.
[2] Catalano O, Antonaci S, Moro G, et al. Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. Eur Heart J 2009;30:2241–8.
[3] Letsas KP, Efremidis M, Weber R, et al. Epsilon-like waves and ventricular conduction abnormalities in subjects with type 1 ECG pattern of Brugada syndrome. Heart Rhythm 2011;8:674–8.
[4] Hoogendijk MG. Diagnostic dilemmas: overlapping features of brugada syndrome and arrhythmogenic right ventricular cardiomyopathy. Front Physiol 2012;3:144.
[5] Peters S, Trümmel M, Denecke S, et al. Results of ajmaline testing in patients with arrhythmogenic right ventricular dysplasia–cardiomyopathy. Int J Cardiol 2004;95:207–10.
[6] Peters S, Trümmel M, Koehler B, et al. QRS fragmentation in standard ECG as a diagnostic marker of arrhythmogenic right ventricular dysplasia–cardiomyopathy. Heart Rhythm 2008;5:1417–21.
[7] Zhang L, Riera ARP, Pu J, et al. Are epsilon waves in ARVD “the right precordial leads only” phenomena? Europace 2006;8(Suppl 1):S265/4.
[8] Papavassiliu T, Wolpert C, Flüchter S, et al. Magnetic resonance imaging findings in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004;15:1133–8.
[9] Zumhagen S, Speier T, Rolink J, et al. Absence of pathognomonic or inflammatory patterns in cardiac biopsies from patients with Brugada syndrome. Circ Arrhythm Electrophysiol 2009;2:16–23.
[10] Koogmann TT, Beekman L, Alders M, et al. Exclusion of multiple candidate genes and large genomic rearrangements in SCN5A in a Dutch Brugada syndrome cohort. Heart Rhythm 2007;4:752–5.
[11] Tada H, Aihara N, Ohe T, et al. Arrhythmogenic right ventricular cardiomyopathy underlies syndrome of right bundle branch block, ST-segment elevation, and sudden death. Am J Cardiol 1998;81:519–22.